Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this module, Philip Mease, MD, MACR, and Atul Deodhar, MD, MRCP, discuss key studies that will affect the management of patients with axial psoriatic arthritis (axPsA) and axial spondyloarthritis (axSpA) including new data from the CorEvitas PsA/SpA Registry revealing the high symptom burden in patients with axPsA and axSpA, the COAST trial analysis showing potential sex-related differences in axSpA in terms of the disease severity and treatment outcomes, the impact of fibromyalgia on patient-reported outcomes and quality of life, what the results of the C-OPTIMISE trial teach us about drug-free remission, the shift from a consensus-based to a data-based approach for MRI in diagnosing axSpA, and the safety and immunogenicity results in adults with autoimmune inflammatory rheumatic diseases (AIIRD) who were vaccinated for COVID-19.